1996
DOI: 10.1177/019262339602400109
|View full text |Cite
|
Sign up to set email alerts
|

Bile Acids in the Assessment of Hepatocellular Function

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
12
0

Year Published

1997
1997
2023
2023

Publication Types

Select...
5
3
2

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(15 citation statements)
references
References 114 publications
0
12
0
Order By: Relevance
“…In general, bile acid concentrations had ≥ twofold increases in the higher-dose groups compared to concurrent vehicle controls. Increases of this magnitude are indicative of impaired bile flow or (intrahepatic) cholestasis, the causes of which include physical disruption of bile flow through the biliary system or perturbation of bile acid formation and excretion at the cellular level 109 . Direct bilirubin concentration, another marker of cholestasis, was minimally elevated in the high-dose groups of PFBS and PFOS.…”
Section: Discussionmentioning
confidence: 99%
“…In general, bile acid concentrations had ≥ twofold increases in the higher-dose groups compared to concurrent vehicle controls. Increases of this magnitude are indicative of impaired bile flow or (intrahepatic) cholestasis, the causes of which include physical disruption of bile flow through the biliary system or perturbation of bile acid formation and excretion at the cellular level 109 . Direct bilirubin concentration, another marker of cholestasis, was minimally elevated in the high-dose groups of PFBS and PFOS.…”
Section: Discussionmentioning
confidence: 99%
“…In general, bile acid concentrations in PFDA and PFNA studies had greater than a threefold increase in the higher-dose groups compared to concurrent vehicle controls. Increases of this magnitude are indicative of impaired bile flow or (intrahepatic) cholestasis, the causes of which include physical disruption of bile flow through the biliary system or perturbation of bile acid formation and excretion at the cellular level 135 . In addition, total bilirubin concentration, another marker of cholestasis, was substantially elevated in most high-dose PFNA and PFDA groups.…”
Section: Discussionmentioning
confidence: 99%
“…UDCA has been isolated from polar bear bile (Kurozumi, Harano & Ayaki 1974) and used to treat cholestatic liver disease in humans (Hofman 1984). UDCA has many reported pharmacological effects for humans, such as improvement of liver function, digestion and absorption of dietary lipid and fat‐soluble vitamins by stimulating bile secretion (Ward, Brogden, Heel, Speight & Avery 1984; Heller, Martinet, Henrion, Schapira & Gallez 1990; Thompson 1996). In mammals, UDCA can modulate immunoglobulin (Ig) expression not only qualitatively, but also quantitatively (Zuchner, Sternsdorf, Szostecki, Heathcote, Cauch & Will 1997).…”
Section: Introductionmentioning
confidence: 99%